Co-Operation Opportunities within Swiss Biotech
Besides publication in the different media as listed below, the Swiss Biotech Association offers co-operation opportunities to enhance your visibility in the biotech community.
Further information
List of publications with advertising opportunities (data as per end of 2009 - not representative):
| Journal | Circulation | Geographic Distribution | Customer Segments |
| American Biotech Laboratory | 50'000 | USA | 22% biophysics, 19% biochemistry, 17% chemistry, 11% biotech |
| American Laboratory | 70'000 | USA/Canada | 21% chemistry, 15% environmentals / analytics, 15% pharma |
| Bio Tech International | 24'000 | 74% Europe, 18% Asia |
12% pharma, 13% molecular biology, 11% biochemistry |
| Bio-IT World | |||
| BioExecutive International | 14'000 | 79% North America, 21% Europe |
53% biopharmaceuticals / biotech, 19% clinical research |
| BIOforum | 15'000 | 90% DE | 35% pharma, 28% biotech, 12% university |
| BIOforum Europe | 26'000 | 20% DE,A,CH, 18% UK, 22% Scandinavia, 11% France |
35% biotech, 28% pharma/food/cosmetics, 12% university |
| Biopharm International | 30'000 | 74% North America, 17% Europe, 7% Asia |
33% biopharm, 23% pharma, 10% research |
| BioProcess International | 30'000 | 67% USA/CDN, 33% EU |
41% biopharm, 10% clinical research, 9% biotech |
| BioScience Technology | 55'000 | USA | 22% university, 18% private research, 17% pharma, 16% biotech |
| BioTechniques | 80'000 | 76% USA/Cdn, 20% Europe, 2% Asia |
16% molecular biology, 14% biochemistry, 12% cell biology, 11% microbiology |
| Biotechnologies & Finances | |||
| cav - chemie-anlagen + verfahren | 35'000 | D/CH/A | 55% chemistry/pharma, 12% plant manufacture |
| Chemanager | 43'000 | D/CH/A | 51% chemistry, 33% biotech |
| Chemanager Europe | 15'000 | 18% UK, 25% D/CH/A, 13% F, 9% Benelux, 8% Eastern Europe, 8% I, 6% Scandinavia, 5% E/P |
51% chemistry, 33% biotech |
| Chemie plus | 13'000 | CH | |
| Chemische Rundschau | 12'000 | CH | 59% chemistry, 14% biotech |
| CITplus | 26'000 | D/CH/A | 41% chemistry, 30% engineering, 9% pharma |
| clb - Chemie in Labor und Biotechnik | 5'000 | D/CH/A | |
| Contract Pharma | 20'000 | 80% USA | 39% pharma, 10% CMO, 19% CRO |
| Contract Services Europe | |||
| cpp chemical plants + processing | 25'000 | 67% Europe, 25% Asia, 7% Americas |
55% chemistry / pharma, 12% plants |
| Drug Discovery & Development | 35'000 | 95% USA | 44% pharma, 23% biotech, 7% biopharm |
| European Biotechnology News | 15'000 | 91% Europe | 35% pharma, 19% suppliers, 18% university, 15% research |
| European Pharma Manufacturer | 13'000 | 30% UK, 14% F, 13% D, 11% Scandinavia |
|
| Forschung und Diagnostik | 8'000 | D/CH/A | 42% medical, 20% pharma |
| GEN | 80'000 | 70% USA | 29% cell culture, 28% genomics, 28% separation |
| GIT Labor-Fachzeitschrift | 25'000 | D/CH/A | 35% chemistry, 18% pharma, 11% university, 10% biotech |
| GIT Laboratory Journal Europe | 27'000 | 22% UK/IR, 20% D/A/CH, 13% Scandinavia, 11% F, 10% Benelux |
35% chemistry, 19% pharm, 6% food, 5% biotech |
| GIT ReinraumTechnik | 10'000 | D/CH/A | 25% pharma, 11% food, 8% biotech |
| GIT Separation | 25'000 | D/CH/A | 39% chemistry, 21% pharma, 13% biotech, 13% university |
| GIT Steriltechnik | 10'000 | D/CH/A | 30% pharma, 21% biotech, 17% food, 13% medical, 9% cosmetic |
| Industrial Biotechnology | 4'000 | ||
| International Labmate | 38'000 | 78% EU, 21% middle east |
46% industry, 37% hospital, 14% university |
| Journal of Biomoldecular Screening | |||
| Journal of the Association of Lab Automation | |||
| Lab Asia | 25'000 | 17% China, 11% India, 10% Malaysia, 8% Taiwan, 8% Korea, 7% Australia |
52% industry, 37% hospital, 8% government |
| LabBusiness | 25'000 | Canada | 31% chemical/pharma, 29% environmental, 27% food |
| Labmate UK | 10'000 | UK | 49% industry, 32% hospitals |
| Labo | 5'000 | D/CH/A | 21% chemistry / biotech, 15% university |
| Laboratorio y Analisis | 27'000 | 36% Mexico, 14% Argentina, 9% Brazil, 8% Colombia, 7% Chile, 4% Venezuela |
31% chemistry, 20% food, 15% medical, 10% processing |
| Laborjournal | 258000 | D/CH/A | 29% universities, 26% industry |
| Laborpraxis | 23'000 | D/CH/A | 39% chemistry / pharma, 13% university, 5% clinical labs |
| LaborpraxisChina | 10'000 | ||
| Laborwelt | 20'000 | D/CH/A | 37% university, 23% research, 13% pharma / biotech |
| Lebensmittel & Biotechnologie | 2'000 | 80% A, |
|
| Nature | 60'000 | 55% Americas, 30% Europe, 15% Asia |
58% university, 12% industries |
| Nature biotech | 17'000 | 90% North-America | 23% molecular biology, 13% genomics, 8% microbiology |
| Nature Cell Biology | 3'000 | 41% Americas, 39% Europe |
|
| Nature Chemical Biology | |||
| Nature Drug Discovery Reviews | 10'000 | 55% Americas, 35% Europe, 10% Asia |
25% biotech, 21% pharma, 18% university, 11% consultants |
| Nature Genetics | 6'000 | 56% Americas, 18% Europe |
50% research, 40% medical, 10% pharma / biotech |
| Nature Immunology | 3'000 | 46% Americas, 20% Europe |
|
| Nature Medicine | 11'000 | 58% USA, 17% Europe |
70% university / medical, 29% pharma / biotech |
| Nature Methods | 60'000 | 72% USA, 22% Europe |
54% pharma / biotech, 46% university |
| Noticias tecnicas | 26‘000 | 78% South America, 22% E |
21% chemistry, 13% biochemistry, 10% analytics, 10% food, 10% biotech |
| PDA Letter | 10'000 | 48% pharma, 23% biopharma, 11% consultants |
|
| Pharma + Food | 10'000 | D/CH/A | 45% pharma, 15% food, 6% engineering |
| Pharma International | |||
| Pharma Manufacturing | 5'000 | 33% UK, 10% D/CH/A, 7%I, 5% Ost-EU |
80% pharma, 20% suppliers |
| Pharma Processing | 31‘000 | USA | 79% pharma, 6% medical, 6% consulting, 5% university |
| Pharmaceutical Engineering | 21'000 | 62% USA, 7% UK, |
28% engineering, 28% pharma, 10% biotech, 9% supplier |
| Pharmaceutical Science & Technology Today | 2'000 | 51% Europe, 37% USA, 12% Asia |
62% pharma / biotech, 24% university |
| Pharmaceutical Technology | 34'000 | USA | 68% pharma / biopharma, 7% research, 6% university |
| Pharmaceutical Technology Asia | 5'000 | 27% China, 24% Japan, 9% Korea, 7% India, 5% AUS, |
|
| Pharmaceutical Technology Europe | 18‘000 | 21% UK, 17% D/CH/A, 13% F, 10% Scandinavia, 7% I, 6% E, 5% NL, 5% Eastern Europe |
69% pharma, 11% contract services, 7% medical |
| Pristine Processing | 20'000 | USA | 36% pharma, 14% biotech, 11% food |
| Process | 24'000 | D/CH/A | 50% chemistry / pharma, 29% engineering |
| Process China | 30'000 | ||
| Process PharmaTEC | 11'000 | D/CH/A | 46% pharma / chemistry, 13% food, 10% engineering, 9% university, 8% research |
| Process PharmaTEC international | 15'000 | 26%D/CH/A, 16% Americas, 11% Asia, 8% I, 5% Scandinavia, 5% I |
46% pharma / chemistry, 13% food, 10% engineering, 9% university, 8% research |
| Process worldwide | 25'000 | ||
| Schreening - Trends in Drug Discovery | 10'000 | 39% D/CH/A, 24% UK, 13% F/B, 12% Scandinavia |
59% pharma, 20% biotech, 15% research |
| Transkript | 10‘000 | D/CH/A | 28% biotech, 25% university, 17% suppliers, 18% research |
| UK Laboratory | 17‘500 | UK | 18% analytics, 14% chemistry, 9% biochemistry, 7% biotech, 7% pharma |




